Novartis and Schrödinger Forge $150M Drug Discovery Partnership with Billions in Potential Milestones

Partnership Details:
Novartis has entered into a multiyear, multi-target collaboration and license agreement with Schrödinger, a company specializing in computational drug discovery13.

Financial Terms:
Novartis will pay $150 million upfront to Schrödinger, with potential for billions more in milestone payments on the back end23.

Objective:
The partnership aims to work on several preclinical drug programs, leveraging Schrödinger's computational drug discovery capabilities13.

Company Background:
Schrödinger was founded in 1990 and has been a key player in the field of computational drug discovery1.

Potential Impact:
This partnership could significantly enhance Novartis's drug discovery efforts, potentially leading to new therapeutic options for various diseases23.

Sources:

1. https://endpts.com/novartis-pays-150m-upfront-to-schrodinger-in-new-drug-deal/

2. https://biotechjobs.io/2024/11/12/novartis-pays-schrodinger-150m-bets-billions-on-the-back-end-to-form-drug-discovery-pact/

3. https://www.fiercebiotech.com/biotech/novartis-pays-schrodinger-150m-bets-billions-back-end-form-drug-discovery-pact